Provided by Tiger Trade Technology Pte. Ltd.

Tenax Therapeutics

2.12
-0.2000-8.62%
Post-market: 2.150.0300+1.42%19:59 EDT
Volume:5.15M
Turnover:11.42M
Market Cap:79.34M
PE:-1.44
High:2.38
Open:2.29
Low:2.12
Close:2.32
52wk High:19.40
52wk Low:1.31
Shares:37.42M
Float Shares:17.52M
Volume Ratio:0.63
T/O Rate:29.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4685
EPS(LYR):-1.3412
ROE:-59.80%
ROA:-37.70%
PB:0.70
PE(LYR):-1.58

Loading ...

Tenax Therapeutics Discloses ADAR1 Capital Management as Beneficial Owner in Form 3 Filing

Reuters
·
Aug 25

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Aug 13

Tenax Therapeutics downgraded to Neutral from Buy at Chardan

TIPRANKS
·
Aug 11

Tenax Therapeutics Price Target Cut to $5.00/Share from $39.00 by Evercore ISI Group

Dow Jones
·
Aug 11

Evercore ISI Downgrades Tenax Therapeutics to In Line From Outperform, Adjusts PT to $5 From $39

MT Newswires Live
·
Aug 11

Tenax Therapeutics Inc : William Blair Cuts to Market Perform Rating

THOMSON REUTERS
·
Aug 11

Tenax Therapeutics price target lowered to $4 from $26 at Leerink

TIPRANKS
·
Aug 11

Tenax Therapeutics Inc : Canaccord Genuity Cuts Target Price to $4 from $35

THOMSON REUTERS
·
Aug 11

Tenax Therapeutics downgraded to Market Perform from Outperform at William Blair

TIPRANKS
·
Aug 11

U.S. Stocks on the MOVE-Microsoft, Coastal Financial

Reuters
·
Aug 11

Tenax, Sionna Shares Sink After Trial Failures

Dow Jones
·
Aug 10

Tenax Therapeutics Exec Says Two Deaths Occurred During Double-Blind Phase, with Investigators Determining Both were Unrelated to Tnx-103- Conf Call

THOMSON REUTERS
·
Aug 10

Quanterix Q2 Revenue Rises 34% but Cuts 2026 Outlook

Reuters
·
Aug 10

U.S. Stocks on the MOVE-Apple, Barrick Mining, AbCellera Biologics

Reuters
·
Aug 10

Top Premarket Decliners

MT Newswires Live
·
Aug 10

Orion: Tenax's Trial Did not Reach Primary Endpoint

Reuters
·
Aug 10

Tenax Therapeutics Falls After Heart Drug Misses Late-Stage Study Goal

Reuters
·
Aug 10

Tenax Therapeutics Shares Plunge 84.4% Premarket After Co's Heart Drug Did not Meet Main Goal in Late-Stage Study

THOMSON REUTERS
·
Aug 10

Tenax Therapeutics Phase 3 Level Trial Misses Primary Endpoint

Reuters
·
Aug 10

Tenax Says Phase 3 LEVEL Trial of TNX-103 in PH-HFpEF Misses Primary Endpoint on 6-Minute Walk Distance

Reuters
·
Aug 10